铁死亡:心肌缺血再灌注损伤分子机制和药物治疗研究新靶点

Ferroptosis:Novel Research Targets of Molecular Mechanism and Drug Therapy for Myocardial Ischemia-Reperfusion Injury

心肌缺血/再灌注损伤(I/R)是再灌注治疗的重要并发症,也是心血管疾病和急危重症患者死亡的主要原因之一,其发病机制复杂,目前临床上尚缺乏有效的防治措施。铁死亡(ferroptosis)是近年来发现的一种全新的调节性细胞死亡方式,是各类疾病发病机理及治疗靶点的热点研究领域。已有研究指出铁死亡与心肌I/R的病理生理过程密切相关。本文综述了近年来铁死亡在心肌I/R中的相关研究进展,以期为心肌I/R的预防和治疗提供新参考。

Myocardial ischemia-reperfusion injury(I/R)is an essential complication of reperfusion therapy,and it is also one of the significant causes of death in patients with cardiovascular disease and critical illness.Due to the complex pathogenesis,there is still a lack of effective prevention and treatment measures of myocardial I/R in clinical practice.Fer⁃roptosis is a novel regulatory cell death found recently,which has become a research focus in the pathogenesis and thera⁃peutic targets of many diseases.Studies have demonstrated a close association between myocardial I/R and ferroptosis.We reviewed the current research progress of ferroptosis in myocardial I/R,aiming to provide a new reference for preventing and treating myocardial I/R.